VIVUS to Present at Two Upcoming Investor Conferences

MOUNTAIN VIEW, Calif., Dec. 3, 2010 /PRNewswire-FirstCall/ -- VIVUS, Inc. (Nasdaq: VVUS) today announced that senior management will present an overview of the company at two investment conferences during the month of December.

The conference presentation schedule is as follows:

Canaccord Genuity Cardiovascular, Diabetes & Obesity Conference

December 8, 2010 at 12:30 p.m. PT

Nikko Hotel, San Francisco, CA

Presenter: Charles Bowden, MD, director of clinical development

2010 Deutsche Bank BioFEST Conference

December 14, 2010 at 4:05 p.m. ET

Four Seasons Hotel, Boston, MA

Presenter: Timothy Morris, chief financial officer

A live audio webcast and 30-day archive of the presentations will be available at


VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health. The company's lead product in clinical development is QNEXA®, which also is in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea. In the area of sexual health, VIVUS is in phase 3 development with avanafil, a PDE5 inhibitor being studied for the treatment of erectile dysfunction. For more information about the company, please visit



Investor Relations:

The Trout Group

Timothy E. Morris

Brian Korb

Chief Financial Officer

[email protected]